Strides ‘Evaluating’ Mylan Claims Over Factory Lapses Cited By FDA
This article was originally published in PharmAsia News
Executive Summary
Drug firm Strides Shasun Ltd says it is "evaluating" claims from Mylan Inc involving US Food and Drug Administration complaints about three plants that the Indian company sold to the global generics drug giant as part of a high-profile $1.75bn deal two years ago.